All In Biotech

NDA 020694 · Janssen Pharma

Sporanox

Itraconazole · Oral

Orphan

Last checked: Nov 19, 2026Latest source record: Dec 6, 1996 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Dec 6, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

507

27 Phase 3, 40 recruiting

FAERS reports

11,784

10,489 serious, 2,277 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 6, 1996 Original approval · Type 6 - New Indication (no longer used) Review
1 products under this application
  • SPORANOX · ITRACONAZOLE 100MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Itraconazole" as an intervention, any sponsor and status, largest first.

All 507 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction1,191
  • drug ineffective1,144
  • off label use632
  • pyrexia589
  • dyspnoea493
  • pneumonia484
  • nausea468
  • diarrhoea404
  • condition aggravated400
  • febrile neutropenia373
  • fatigue351
  • rash310

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004277
2005192
2006219
2007254
2008291
2009408
2010361
2011621
2012587
2013409
2014373
2015610
2016474
2017517
2018703
2019826
2020868
2021782
2022676
2023676
2024601
2025566
2026492

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sporanox (Itraconazole)

2024 spending

$123K

Beneficiaries

26

82 claims

Per beneficiary

$4,730

$12.40 per unit

View as table
YearSpending
2020$509,944
2021$247,250
2022$307,486
2023$196,502
2024$122,988

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 970 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.